Enlivex Therapeutics reports Q3 net loss $5.7M vs $3.4M last year

As of September 30, 2022, Enlivex had cash and cash equivalents of $57.7 million. The Company believes its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements through the third quarter of 2024. "We are continuing to execute our stated operating plan across the different clinical verticals," said Oren Hershkovitz, Ph.D., Chief Executive Officer of Enlivex. "Our oncology program now includes two clinical trials that have initiated patient enrollment. These trials were initiated following a set of preclinical studies that provided strong a scientific rationale for the potential effect of Allocetra(TM), alone and in combination with a PD1 checkpoint inhibitor, in patients with advanced solid tumors who have poor treatment alternatives."